A Global Spotlight on CLL: Shifting Strategies and Optimizing Outcomes

With the treatment paradigm for chronic lymphocytic leukemia (CLL) shifting from chemoimmunotherapy to targeted agents, patients can look forward to tailored treatment strategies, improved long-term disease control and outcomes, and a better quality of life. Optimizing this new, complex therapeutic environment requires clinicians to be up-to-date on the latest guidelines and recommendations, as well as novel and emerging treatment options. Join Drs. Ghia, XXX, and XXX, as they discuss prognostic biomarkers, review guidelines and evidence supporting targeted therapies, and examine strategies for the management of patients with relapsed/refractory CLL and therapeutic intolerance. 

Engage with our experts in this 60-minute global webcast that will illuminate the integration of emerging data into everyday clinical workflows to improve therapeutic management of patients with CLL and prefigure the use of emerging therapies as availability expands across the globe. 

1. Assess testing strategies that may inform clinical decision-making in the management of CLL. 

2. Utilize updated guidelines and evidence supporting the integration of targeted agent classes in CLL as single agents or as part of combination regimens including continuous therapy, fixed-duration options, and novel combinatorial regimens.

3. Evaluate recent clinical evidence on current and emerging therapeutic approaches that have been evaluated for the treatment of patients with R/R CLL and/or therapeutic intolerance. 

Supported through an independent educational grant from Merck.

Global pathologists, hematologists, medical oncologists, and secondary audiences of oncology physician associates (PAs) and nurse practitioners (NPs). 

Dr. Ghia reports the following financial relationships: 

Advisory Board and Consultant: AbbVie Inc.; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; Loxo Oncology/Lilly; MSD; and Roche 

Grants and Research Support: AbbVie Inc.; AstraZeneca; Bristol Myers Squibb Company; and Janssen Pharmaceuticals, Inc.

Dr. Brown reports the following financial relationships: 

Consultant: AbbVie Inc.; Acerta Pharma/AstraZeneca; Alloplex Biotherapeutics; BeiGene, Inc.; Genentech, Inc./Roche; Grifols Worldwide Operations; HUTCHMED; iOnctura, and Janssen Pharmaceuticals, Inc.; Kite; Loxo Oncology/Lilly; Merck & Co., Inc.; Numab Therapeutics; Pfizer Inc.; and Pharmacyclics LLC 

Research Support: BeiGene, Inc.; Gilead Sciences, Inc.; iOnctura; Loxo Oncology/Lilly; MEI Pharma, Inc.; SecuraBio, Inc.; and TG Therapeutics, Inc. 

The following individuals have no financial relationships to disclose:

• Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer review)
• Nichole Lainhart (Planning Committee/ME)
• Katherine Lee, PharmD (Planning Committee/MRG)
• Susan H. Yarbrough, CHCP (Planning Committee)
• Sandra Caballero, PharmD (Planning Committee)
• Sharon Tordoff (Planning Committee)